Advertisement

Osteoporosis and Cardiovascular Risk

  • Giancarlo Isaia
  • Lorenzo Marchese
  • Margherita Marchetti
  • Mario Bo
Chapter

Abstract

Osteoporosis and cardiovascular diseases are two of the major public health problems: both are associated with high morbidity and mortality, increased recourse to hospital services, loss of independence, increased risk of institutionalization and high health-related costs. The socio-economic consequences of both these diseases are very important bearing in mind the facts that OP is the second highest world health problem after CVD, and this number will increase with the growth of the elderly population over the next decades.

References

  1. 1.
    Winkelmann BR. American Heart Association scientific sessions. Expert Opin Investig Drugs. 2004;13:435–45.CrossRefPubMedGoogle Scholar
  2. 2.
    Tanko LB, Christiansen C, Cummings SR. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res. 2005;20:1912–20.CrossRefPubMedGoogle Scholar
  3. 3.
    Chiang CH, Liu CJ, Chen PJ, Huang CC, Hsu CY, Chen ZY, Chan WL, Huang PH, Chen TJ, Chung CM, Lin SJ, Chen JW, Leu HB. Hip fracture and risk of acute myocardial infarction: a nationwide study. J Bone Miner Res. 2013;28:404–11.CrossRefPubMedGoogle Scholar
  4. 4.
    Sennerby U, Melhus H, Gedeborg R, Byberg L, Garmo H, Ahlbom A, Pedersen NL, Michaëlsson K. Cardiovascular diseases and risk of hip fracture. JAMA. 2009;302:1666–73.CrossRefPubMedGoogle Scholar
  5. 5.
    Aluoch AO, Jessee R, Habal H, Garcia-Rosell M, Shah R, Reed G, Carbone L. Heart failure as a risk factor for osteoporosis and fractures. Curr Osteoporos Rep. 2012;10(4):258–69.CrossRefPubMedGoogle Scholar
  6. 6.
    Sprini D, Rini GB, Di Stefano L, Cianferotti L, Napoli N. Correlation between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab. 2014;11(2):117–9.PubMedPubMedCentralGoogle Scholar
  7. 7.
    El Maghraoui A, Rezqi A, Mounach A. Vertebral fractures and abdominal aortic calcification in postmenopausal women. A cohort study. Bone. 2013;56:213–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Bastos Gonçalves F, Voûte MT, Hoeks SE, Chonchol MB, Boersma EE, Stolker RJ, Verhagen HJ. Calcification of the abdominal aorta as an independent predictor of cardiovascular events: a meta-analysis. Heart. 2012;98:988–94.CrossRefPubMedGoogle Scholar
  9. 9.
    Simon SP, Fodor D, Muntean L, Poanta L, Cristea P, Rednic S. Bone mineral density, vertebral fractures and body mass index in post-menopausal women with abdominal aortic calcification. Endocr Res. 2014;39:1–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Szulc P. Vascular calcification and fracture risk. Clin Cases Miner Bone Metab. 2015;12(2):139–41.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Frost ML, Grella R, Millasseau SC, Jiang BY, Hampson G, Fogelman I, Chowienczyk PJ. Relationship of calcification of atherosclerotic plaque and arterial stiffness to bone mineral density and osteoprotegerin in postmenopausal women referred for osteoporosis screening. Calcif Tissue Int. 2008;83(2):112–20.CrossRefPubMedGoogle Scholar
  12. 12.
    Fernández-Murga ML, Vinué Á, Caeiro JR. Impact of estrogens on atherosclerosis and bone in the apolipoprotein E-deficient mouse model. Menopause. 2015;22:428–36.CrossRefPubMedGoogle Scholar
  13. 13.
    McCarty MF, Di Nicolantonio JJ. The molecular biology and pathophysiology of vascular calcification. Postgrad Med. 2014;126:54–64.CrossRefPubMedGoogle Scholar
  14. 14.
    Lello S, Capozzi A, Scambia G. Osteoporosis and cardiovascular disease: an update. Gynecol Endocrinol. 2015;31(8):590–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Lee CJ, Wang JH, Chen ML. Serum osteoprotegerin is associated with arterial stiffness assessed according to the cardio-ankle vascular index in hypertensive patients. J Atheroscler Thromb. 2015;22:304–12.CrossRefPubMedGoogle Scholar
  16. 16.
    D'Amelio P, Isaia G, Isaia GC. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. J Endocrinol Investig. 2009;32(4 Suppl):6–9.Google Scholar
  17. 17.
    Wolak T. Osteopontin – a multi-modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis. 2014;236:327–37.CrossRefPubMedGoogle Scholar
  18. 18.
    Evrard S, Delanaye P, Kamel S. Vascular calcification: from pathophysiology to biomarkers. Clin Chim Acta. 2014;438C:401–14.Google Scholar
  19. 19.
    Lai YH, Fang TC. The pleiotropic effect of vitamin D. ISRN Nephrol. 2013;2013:898125.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Querales MI, Cruces ME, Rojas S. Association between vitamin D deficiency and metabolic syndrome. Rev Med Chil. 2010;138:1312–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Pilz S, Verheyen N, Grübler MR, Tomaschitz A, März W. Vitamin D and cardiovascular disease prevention. Nat Rev Cardiol. 2016;13(7):404–17.CrossRefPubMedGoogle Scholar
  22. 22.
    Wang T, Pencina M, Booth S. Vitamin D deficiency and risc of cardiovascular disease. Circulation. 2008;117:503–11.CrossRefPubMedGoogle Scholar
  23. 23.
    Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110:229–38.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Stojanovic OI, Lazovic M, Lazovic M, Vuceljic M. Association between atherosclerosis and osteoporosis, the role of vitamin D. Arch Med Sci. 2011;7(2):179–88.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801–11.CrossRefPubMedGoogle Scholar
  26. 26.
    Cagnacci A, Cannoletta M, Palma F. Relation between oxidative stress and climacteric symptoms in early postmenopausal women. Climacteric. 2015;18(4):1–6.CrossRefGoogle Scholar
  27. 27.
    Anagnostis P, Karagiannis A, Kakafika AI, Tziomalos K, Athyros VG, Mikhailidis DP. Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int. 2009;20:197–207.CrossRefPubMedGoogle Scholar
  28. 28.
    Shoji S. Vitamin K and vascular calcification. Clin Calcium. 2002;12:1123–8.PubMedGoogle Scholar
  29. 29.
    Igase M, Kohara K, Tabara Y. Change in arterial stiffness associated with monthly bisphosphonate treatment in women with postmenopausal osteoporosis. Menopause. 2014;21:962–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Celiloglu M, Aydin Y, Balci P, Kolamaz T. The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis. Menopause. 2009;16:689–93.CrossRefPubMedGoogle Scholar
  31. 31.
    Wu M, Rementer C, Giachelli CM. Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int. 2013;93:365–73.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Samelson EJ, Miller PD, Christiansen C. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res. 2014;29:450–7.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Riancho JA, Salas E, Zarrabeitia MT, Olmos JM, Amado JA, Fernández-Luna JL, González-Macías J. Expression and functional role of nitric oxide synthase in osteoblast-like cells. J Bone Miner Res. 1995;10(3):439–46.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Giancarlo Isaia
    • 1
  • Lorenzo Marchese
    • 2
  • Margherita Marchetti
    • 3
  • Mario Bo
    • 3
  1. 1.Unit of Geriatrics and Metabolic Bone DiseaseMolinette Hospital and School of Geriatric Medicine, University of TorinoTorinoItaly
  2. 2.Presidio AusiliatriceFondazione Don Carlo GnocchiTorinoItaly
  3. 3.Department of GeriatricsCittà della Salute e della Scienza - Molinette Hospital, University of TorinoTorinoItaly

Personalised recommendations